Mass, quality, directionality ¿Which is the real difference between ‘osteopenias’ and ‘osteoporoses’?
The WHO differentiates between osteopenias (simple losses of mineralized bone mass) and osteoporoses (losses with increased fracture risk) based on just the amount of the remaining, densitometrically—assessed bone mineral mass. To note, the strength of a bone does not depend on its mineralized mass...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional de Rosario
2021
|
| Materias: | |
| Acceso en línea: | https://fcmcientifica.unr.edu.ar/index.php/revista/article/view/19 |
| Aporte de: |
| Sumario: | The WHO differentiates between osteopenias (simple losses of mineralized bone mass) and osteoporoses (losses with increased fracture risk) based on just the amount of the remaining, densitometrically—assessed bone mineral mass. To note, the strength of a bone does not depend on its mineralized mass but on the combination of its stiffness (resistance to deformation) and toughness (resistance to split). These ‘structural’ properties result from the quality (stiffness, toughness) and spatial distribution (cortical/trabecular design) of bone tissue. The whole—bone strength is controlled by a feedback mechanism (‘mechanostat’) that adapts tissue distribution to tissue quality as a function of the usage—derived bone strains sensed by osteocytes. Therefore, bone strength does not reflect a metabolically accumulated mass but a biomechanically servo—controlled structure oriented by a well—established organization. Thus, the difference between osteopenias and osteoporoses, regardless of bone mineral data, must be interpreted by assessing the structural impact of the variable interaction of two independent determinants, namely, 1. The directional (‘vectorial’) mechanical environment of the skeleton (mechanostat input), and 2. The non—directional (‘systemic’) endocrine—metabolic environment, which privileges the mineral homeostasis control (essential to bone health) over bone structural integrity, thus tending rather to disturb than co—adjuvate the directional control of bone strength by changing the mechanostat setpoint. The mechanical component (1) must be treated by a directionally specific mechanical stimulation of bones. The metabolic component (2) requires drugs whose systemic effects are strongly conditioned to (1). Treatment success will depend largely on reconsidering osteoporoses as diseases of bone design rather than bone mass. |
|---|